ImmuneOnco Biopharmaceuticals (Shanghai) Inc. (HKG:1541)
Hong Kong
· Delayed Price · Currency is HKD 5.02
+0.22 (4.58%)
Mar 10, 2026, 4:08 PM HKT
HKG:1541 Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
Period Ending | Jun '25 Jun 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| Operating Revenue | 112.1 | 74.15 | 0.39 | 0.54 | 5.07 |
| Other Revenue | 10.73 | 5.39 | 7.31 | 5.15 | 8.74 |
| Revenue | 122.83 | 79.54 | 7.7 | 5.69 | 13.81 |
| Revenue Growth (YoY) | 1584.92% | 933.61% | 35.24% | -58.79% | - |
| Gross Profit | 122.83 | 79.54 | 7.7 | 5.69 | 13.81 |
| Selling, General & Admin | 62.01 | 64.82 | 80.42 | 92.8 | 48.32 |
| Research & Development | 371.67 | 322.76 | 291.94 | 277.35 | 175.95 |
| Operating Expenses | 433.68 | 387.58 | 372.37 | 370.14 | 224.27 |
| Operating Income | -310.85 | -308.04 | -364.67 | -364.45 | -210.47 |
| Interest Expense | -4.47 | -3.45 | -1.52 | -0.79 | -0.89 |
| Interest & Investment Income | 6.45 | 6.38 | 10.8 | 9.51 | 1.64 |
| Currency Exchange Gain (Loss) | -1.94 | 1.79 | 0.1 | 26.11 | -9.13 |
| Other Non Operating Income (Expenses) | -0.02 | -0.02 | -25.92 | -73.27 | -514.83 |
| EBT Excluding Unusual Items | -310.83 | -303.34 | -381.22 | -402.89 | -733.67 |
| Gain (Loss) on Sale of Investments | 7.27 | 14.15 | 1.76 | - | - |
| Gain (Loss) on Sale of Assets | - | - | - | - | 0.56 |
| Asset Writedown | - | -27.4 | - | - | - |
| Other Unusual Items | - | - | - | - | 0.17 |
| Pretax Income | -303.56 | -316.59 | -379.46 | -402.89 | -732.95 |
| Earnings From Continuing Operations | -303.56 | -316.59 | -379.46 | -402.89 | -732.95 |
| Minority Interest in Earnings | 0.87 | 0.74 | - | - | - |
| Net Income | -302.68 | -315.86 | -379.46 | -402.89 | -732.95 |
| Net Income to Common | -302.68 | -315.86 | -379.46 | -402.89 | -732.95 |
| Shares Outstanding (Basic) | 394 | 377 | 362 | 332 | 86 |
| Shares Outstanding (Diluted) | 394 | 377 | 362 | 332 | 86 |
| Shares Change (YoY) | 6.17% | 4.24% | 9.05% | 284.99% | - |
| EPS (Basic) | -0.77 | -0.84 | -1.05 | -1.21 | -8.50 |
| EPS (Diluted) | -0.77 | -0.84 | -1.05 | -1.21 | -8.50 |
| Free Cash Flow | -140.89 | -138.44 | -370.25 | -261.93 | -231.24 |
| Free Cash Flow Per Share | -0.36 | -0.37 | -1.02 | -0.79 | -2.68 |
| Gross Margin | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% |
| Operating Margin | -253.07% | -387.30% | -4739.09% | -6405.13% | -1524.23% |
| Profit Margin | -246.42% | -397.12% | -4931.24% | -7080.74% | -5308.15% |
| Free Cash Flow Margin | -114.70% | -174.06% | -4811.50% | -4603.41% | -1674.69% |
| EBITDA | -302.09 | -297.77 | -352.26 | -352.54 | -202.69 |
| D&A For EBITDA | 8.75 | 10.28 | 12.41 | 11.91 | 7.77 |
| EBIT | -310.85 | -308.04 | -364.67 | -364.45 | -210.47 |
Source: S&P Capital IQ. Standard template. Financial Sources.